COYA Stock — Coya Therapeutics, Inc. Common Stock

Coya Therapeutics, Inc. Common Stock (COYA)

Updated October 16, 2026.

COYA is a Stock. Total return is -7.0% over the past 3.8 years, 115.7 points behind SPY at 108.7%.

Coya Therapeutics is a clinical-stage biotechnology company developing proprietary therapies designed to enhance regulatory T cell function for treating neurodegenerative and inflammatory diseases, including amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and frontotemporal dementia. The company does not currently distribute dividends. As an early-stage biotech firm with no approved products yet, it appeals to investors seeking exposure to novel therapeutic development rather than current income.

COYA performance versus SPY

Price and return data through 2026-10-16.

Total return is -7.0% over the past 3.8 years, 115.7 points behind SPY at 108.7%. Over the past year its total return — price change plus distributions reinvested — is -32.5%. Its deepest 1-year drawdown was 48.6%.

COYA key facts

Asset type

Stock

Asset class

Equity

Inception date

12/29/2022

Distribution frequency

None

Last close

$4.25 (as of 2026-10-16)

Market cap

$99,695,858

Average volume

134190.0

Beta

0.579

Payout ratio

0.0%

EPS

$-1.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

COYA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 48.6%.

Who may consider COYA — and who may not

It is a weaker fit for investors who need monthly cash flow (COYA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on COYA

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions